The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. After reconstitution store at -20ºC. Avoid freeze / thaw cycles.
Constituents: 10% Trehalose, 1% Human serum albumin
It is recommended that 0.5 ml of sterile phosphate-buffered saline be added to the vial.
Following reconstitution short-term storage at 4°C is recommended, and longer-term storage of aliquots at -18 to -20°C. Repeated freeze thawing is not recommended.
FLT4 ligand DHM
Vascular endothelial growth factor C
Vascular endothelial growth factor related protein
Vascular endothelial growth factor-related protein
Growth factor active in angiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR/FLK1) and VEGFR-3 (FLT4) receptors.
Spleen, lymph node, thymus, appendix, bone marrow, heart, placenta, ovary, skeletal muscle, prostate, testis, colon and small intestine and fetal liver, lung and kidney, but not in peripheral blood lymphocyte.
Belongs to the PDGF/VEGF growth factor family.
Undergoes a complex proteolytic maturation which generates a variety of processed secreted forms with increased activity toward VEGFR-3, but only the fully processed form could activate VEGFR-2. VEGF-C first form an antiparallel homodimer linked by disulfide bonds. Before secretion, a cleavage occurs between Arg-227 and Ser-228 producing an heterotetramer. The next extracellular step of the processing removes the N-terminal propeptide. Finally the mature VEGF-C is composed mostly of two VEGF homology domains (VHDs) bound by non-covalent interactions.
Functional Studies - VEGFC protein (Human) (ab83573)
The densitometry scan demonstrates the purified human cell expressed protein exists in multiple isoforms, which differ
according to their level of post-translational modification. The triangle indicates theoretical pI and MW of the protein.
Anti-VEGFC antibody (ab83905) at 1 µg/ml + Recombinant Human VEGFC protein (ab83573) at 0.1 µg
Lane 1 – MW markers; Lane 2 – ab83573 ; Lane 3 – ab83573 treated with PNGase F to remove potential N-linked glycans; Lane 4 – ab83573 treated with a glycosidase
cocktail to remove potential N- and O-linked glycans. Approximately 5 µg of protein was loaded per lane. Drop in MW after treatment with PNGase F indicates presence of N-linked glycans. A possible further drop in MW after treatment with the glycosidase cocktail indicates the possible presence of O-linked glycans. Additional bands in lane 3 and lane 4 are glycosidase enzymes.
SDS-PAGE - VEGFC protein (Human) (ab83573)
2D SDS-PAGE: A sample of VEGFC without carrier protein was reduced and alkylated and focused on a 3-10 IPG strip then run on a 4-20% Tris-HCl 2D gel. Approximately 40 µg of protein was loaded. Spot train indicates presence of multiple isoforms of VEGFC. Spots within the spot train were cut from the gel and identified as VEGFC by protein mass fingerprinting.
has not yet been referenced specifically in any publications.
Publishing research using ab83573? Please let us know so that we can cite the reference in this datasheet.
Customer reviews and Q&As
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Get resources and offers direct to your inboxSign up